Loading data for IRON — first visit, this takes a few seconds.

Preisalarm

Disc Medicine Inc. (IRON)

NasdaqGM: IRON · Echtzeitkurs · USD

80.05

+1.21 (1.53%)

Zum Schluss: Aug 19, 2026, 3:59 PM

1.53% (1D)

Geld	56.05
Marktkapitalisierung	3.08 Mrd
Umsatz (TTM)	n/a
Nettogewinn (TTM)	-245.89 Mio
Beta	2.06
EPS (ttm)	-6.59
KGV (TTM)	n/a
Forward-KGV	-11.06
KBV (TTM)	4.78
KUV (TTM)	n/a
Earnings Date	Nov 5, 2026

Brief	77.67
Volumen	377,081
Ø Vol. (20D)	527,925
Eröffnung	78.53
Vortagesschluss	78.84
Tagesspanne	74.46 - 80.09
52-Wk Range	40.00 - 99.50
Analyst	n/a
Kursziel	n/a
Dividenden	n/a
Ex-Dividenden-Datum	n/a

Über IRON

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood c...

[Mehr lesen]

Branche Biotechnology

Sektor Healthcare

IPO Datum Aug 12, 2020

Mitarbeiter 165

Börse NasdaqGM

Tickersymbol IRON

Website https://www.discmedicine.com

Vollständiges Unternehmensprofil

Finanzielle Entwicklung

Im Jahr 2025 betrug der Umsatz von Disc Medicine 0, ein Anstieg von undefined% im Vergleich zum Vorjahr (0). Der Gewinn lag bei -212.18 Mio, ein Anstieg von 94.03 %.

Finanzberichte

Gewinnüberraschung

Disc Medicine hat die Quartalszahlen am Jul 30, 2026 veröffentlicht:

Umsatz von $0 verfehlt die Erwartungen um $0, mit NaN% Wachstum im Jahresvergleich.

EPS von -1.54 übertrifft die Erwartungen um 0.23, mit 2.53% Wachstum im Jahresvergleich.

Nächste Ergebnisveröffentlichung

Disc Medicine Inc. wird voraussichtlich die Quartalszahlen veröffentlichen am Nov 5, 2026, vor Börseneröffnung.
Analysten erwarten einen Umsatz von ... Upgrade

Nachrichten

vor 2 Monaten · Simply Wall St.

How Investors May Respond To Disc Medicine (IRON) Expanding Pre-Approval Access To Bitopertin For Porphyria Patients

Disc Medicine has launched a U.S. expanded access program for its investigational drug bitopertin, allowing eligible erythropoietic protoporphyria and X-linked protoporphyria patients aged 12 and abov...

vor 2 Monaten · MarketBeat

Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges

Disc Medicine (NASDAQ:IRON) Chief Executive Officer John Quisel said patient demand for the company’s bitopertin program in erythropoietic protoporphyria, or EPP, remains strong after the company enro...

vor 3 Monaten · Simply Wall St.

A Look At Disc Medicine (IRON) Valuation After Legal Probes And FDA Complete Response Letter

Disc Medicine (IRON) stock has been in focus after law firms began investigating potential securities claims linked to allegedly misleading business information following an FDA Complete Response Lett...

vor 4 Monaten · Motley Fool

Disc Medicine Insider Sells $380K in Stock Amid 70% One-Year Surge

Disc Medicine advances therapies for serious blood disorders; a key insider recently trimmed their stake amid strong one-year share gains.

vor 5 Monaten · Simply Wall St.

Evaluating Disc Medicine (IRON) After Recent Share Moves And Conflicting Valuation Signals

Event Overview and Immediate Context Disc Medicine (IRON) has drawn fresh attention after recent share price moves, with the stock up about 3% over the past day but showing a negative return over the ...

Seite 1 von 2

Disc Medicine Inc. (IRON)